title: Sarcopenia Trials in Specific Diseases: Report by the International Conference on Frailty and Sarcopenia Research Task Force.
abstract: Muscle atrophy occurs as a consequence of a number of conditions, including cancer, chronic obstructive pulmonary disease (COPD), diabetes mellitus, heart failure, and other chronic diseases, where it is generally a predictor of poor survival. It also occurs as a consequence of disuse and an age-related loss of muscle mass and strength (sarcopenia). The aims of the 2016, International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force were to examine how these specific chronic conditions have been employed in treatment trials thus far and how future trials using these patient groups might be designed for efficient identification of effective sarcopenia interventions. Functional limitations assessed as gait speed, distance walked over a set time period, or other attributes of physical performance have been suggested as outcome measures in sarcopenia trials. Indeed, such measures have already been used successfully in a number of trials aimed at preventing disability in older adults.
authors.affiliation: Bruno Vellas, MD. Gérontopôle, CHU Toulouse; Service de Médecine Interne et Gérontologie Clinique. 170 Avenue de Casselardit, 31059 Toulouse, France. Phone: +33 (0)5 6177-6425; Fax: +33 (0)5 6177-6475. E-mail: vellas.b@chu-toulouse.fr.
authors.forename: B
authors.initials: B
authors.lastname: Vellas
authors.forename: R
authors.initials: R
authors.lastname: Fielding
authors.forename: S
authors.initials: S
authors.lastname: Bhasin
authors.forename: F
authors.initials: F
authors.lastname: Cerreta
authors.forename: B
authors.initials: B
authors.lastname: Goodpaster
authors.forename: J M
authors.initials: JM
authors.lastname: Guralnik
authors.forename: S
authors.initials: S
authors.lastname: Kritchevsky
authors.forename: V
authors.initials: V
authors.lastname: Legrand
authors.forename: C
authors.initials: C
authors.lastname: Forkin
authors.forename: J
authors.initials: J
authors.lastname: Magaziner
authors.forename: J E
authors.initials: JE
authors.lastname: Morley
authors.forename: L
authors.initials: L
authors.lastname: Rodriguez-Manas
authors.forename: R
authors.initials: R
authors.lastname: Roubenoff
authors.forename: S
authors.initials: S
authors.lastname: Studenski
authors.forename: D T
authors.initials: DT
authors.lastname: Villareal
authors.forename: M
authors.initials: M
authors.lastname: Cesari
mesh_terms: D015502:Absorptiometry, Photon; D026683:Advisory Committees; D019138:Antibodies, Blocking / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D004035:Diet Therapy; D005081:Exercise Therapy; D005684:Gait; D006333:Heart Failure / Q000150:complications; D006620:Hip Fractures / Q000150:complications; D006801:Humans; D008279:Magnetic Resonance Imaging; D009682:Magnetic Resonance Spectroscopy; D009133:Muscular Atrophy / Q000150:complications / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000628:therapy*; D009765:Obesity / Q000150:complications; D017063:Outcome Assessment, Health Care; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications; D055948:Sarcopenia / Q000150:complications / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000628:therapy*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D000070857:Walk Test
chemical_list: D019138:Antibodies, Blocking; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C000596367:bimagrumab